All Insilico Medicine articles
-
ArticleAI builds dual-action cancer drug targeting PKMYT1
New research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.